Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FL922
- Development stage
- Preclinical
- Lead developer
- Canget BioTekpharma
- Modality
- Small Molecules
01
Overview
FL922 is a small molecule camptothecin analog currently in preclinical development by Canget BioTekpharma for the treatment of head and neck cancer. As an analog of FL118, it is designed to inhibit the expression of anti-apoptotic proteins, most notably survivin, as well as other members of the Inhibitor of Apoptosis (IAP) family such as Mcl-1, XIAP, and cIAP2. FL118 and its derivatives function by suppressing the promoter activity of these genes, thereby overcoming treatment resistance in various solid tumors. FL922 is currently in the in vitro testing phase, aimed at improving the pharmacological profile and therapeutic efficacy of the parent compound.
02
Targets
BIRC5 (Survivin)
Beyond the preview
Go deeper on FL922.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FL922.